Philip Deane's Colleagues at SCYNEXIS
Philip Deane's Contact Details
201-884-5485
Greater New York City Area
SCYNEXIS
Philip Deane's Company Details
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.